文献速递神经肿瘤

ANXA5基因多态性对胶质瘤风险及患者预后的影响

Impact of ANXA5 polymorphisms on glioma risk and patient prognosis.
PubMed 文献 · J Neurooncol · 2018-12-07

该研究在中国汉族人群中检测593例胶质瘤患者与589名健康对照的ANXA5六个单核苷酸多态性,发现rs117677079与胶质瘤风险升高及预后不良相关,rs145619195 CT基因型可能降低易感性和改善预后,单倍型GACCG显著降低胶质瘤易感性。

要点

  • rs117677079与胶质瘤风险升高相关(OR 1.64,p=0.003),尤其高级别胶质瘤预后更差(HR 1.76,p=0.005)。
  • rs145619195 CT基因型可能降低胶质瘤易感性(OR 0.63,p=0.024)并改善预后(HR 0.20,p=0.025)。
  • 单倍型GACCG显著降低胶质瘤易感性(OR 0.61,p=0.003)。

核心结论

  • 本研究首次提供ANXA5多态性影响胶质瘤易感性和预后的证据,提示ANXA5变异可能在胶质瘤病因学中具有潜在作用。

研究设计与样本

  • 在中国汉族人群中,采用Agena MassARRAY对593例胶质瘤患者和589名健康对照的ANXA5六个单核苷酸多态性进行基因分型。
  • 使用逻辑回归模型计算比值比(OR)和95%置信区间(CI),采用log-rank检验、Kaplan-Meier分析和Cox回归模型评估多态性与生存的关联。

主要发现

  • rs117677079多态性与胶质瘤风险升高强烈相关(OR 1.64,p=0.003),并与胶质瘤预后不良相关,尤其在高级别胶质瘤中(HR 1.76,p=0.005)。
  • rs145619195 CT基因型可能降低胶质瘤易感性(OR 0.63,p=0.024)并改善预后(HR 0.20,p=0.025)。
  • 单倍型分析显示,block(rs41278075、rs2306420、rs117677079、rs2306415和rs1131239)中的单倍型「GACCG」显著降低胶质瘤易感性(OR 0.61,p=0.003)。
  • 年龄、切除范围和化疗是胶质瘤患者的关键预后因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioma, the most common primary malignant brain tumor, is highly malignant with a poor prognosis. We aimed to clarify the relevance of ANXA5 polymorphisms to glioma risk and prognosis among the Chinese Han population. METHOD: Six single-nucleotide polymorphisms (SNPs) of ANXA5 were genotyped by Agena MassARRAY in 593 glioma patients and 589 healthy controls. Logistic regression model was used to calculate odds ratios (OR) and 95% confidence intervals (CI). The association between polymorphisms and survival were evaluated using the log-rank test, Kaplan-Meier analysis and Cox regression model. RESULTS: We found that rs117677079 polymorphism was strongly associated with an increased risk of glioma (OR 1.64, p = 0.003) and a worse prognosis for glioma, especially in high-grade glioma (HR 1.76, p = 0.005). Whereas, rs145619195 CT genotype might weaken the susceptibility (OR 0.63, p = 0.024) and prognosis (HR 0.20, p = 0.025) of glioma. Haplotype analysis showed that haplotype ″GACCG″ in the block (rs41278075, rs2306420, rs117677079, rs2306415 and rs1131239) significantly decreased the susceptibility of glioma (OR 0.61, p = 0.003). Furthermore, we also found that age, extent of resection and chemotherapy were key prognostic factors in glioma patients. CONCLUSION: This study firstly provided evidence for the impact of ANXA5 polymorphism on the susceptibility and prognosis of glioma, suggesting ANXA5 variants might have potential roles in the etiology of glioma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Guo X, Song J, Zhao J, et al. Impact of ANXA5 polymorphisms on glioma risk and patient prognosis. J Neurooncol. 2018. PMID: 30536196. doi:10.1007/s11060-018-03069-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。